Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atomo DiagnosticsASX:AT1 3-Year EPS without NRI Growth Rate is 38.30% as of Jun. 2026, which is 256% above its 10-year median of 10.75. The stock has 4 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Atomo Diagnostics ranks better than 83.23% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 38.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 16.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of Atomo Diagnostics was 38.30% per year. The lowest was 3.10% per year. And the median was 10.75% per year.
Atomo Diagnostics (ASX:AT1) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Atomo Diagnostics 3-Year EPS without NRI Growth Rate Related Terms
ASX:AT1 vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Atomo Diagnostics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atomo Diagnostics 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Atomo Diagnostics's 3-Year EPS without NRI Growth Rate falls into.
Atomo Diagnostics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 38.30% mean?
Atomo Diagnostics (ASX:AT1) has a 3-Year EPS without NRI Growth Rate of 38.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Atomo Diagnostics and its competitors. This is 256% above median its historical median of 10.75. Over the past decade, Atomo Diagnostics' 3-Year EPS without NRI Growth Rate has ranged from 3.10 to 38.30. According to the industry distribution chart, Atomo Diagnostics ranks #111 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 16.8%.
Is Atomo Diagnostics' 3-Year EPS without NRI Growth Rate too high?
Atomo Diagnostics' current 3-Year EPS without NRI Growth Rate of 38.30% is 256% above median its 10-year median of 10.75. Over the past 10 years, this metric has ranged from a low of 3.10 to a high of 38.30. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Atomo Diagnostics' value of 38.30% is 375.8% above this industry median. Based on the distribution chart, Atomo Diagnostics ranks #111 out of 662 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Atomo Diagnostics' 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Atomo Diagnostics ranks #111 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places Atomo Diagnostics in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Atomo Diagnostics' value of 38.30% is 375.8% above this benchmark. Historically, Atomo Diagnostics' own 3-Year EPS without NRI Growth Rate has ranged from 3.10 to 38.30 over the past decade. While the company's 10-year median is 10.75 vs. the industry median of 8.05, Atomo Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atomo Diagnostics's current 3-Year EPS without NRI Growth Rate of 38.30% is 375.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Atomo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atomo Diagnostics's current 3-Year EPS without NRI Growth Rate is 38.30%, which is 256% above median its own 10-year median of 10.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.03, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 38.30%, which is 256% above median its 10-year median of 10.75 and 375.8% above the Medical Devices & Instruments industry median of 8.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current 3-Year EPS without NRI Growth Rate is 38.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AT1 has been successfully added to your 
